Page last updated: 2024-09-04

celastrol methyl ester and Bone Loss, Perimenopausal

celastrol methyl ester has been researched along with Bone Loss, Perimenopausal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Han, W; Jia, Y; Lu, X; Peng, J; Qian, Y; Sun, P; Wang, Y; Yang, Q; Zhang, T; Zhao, K	1

Other Studies

1 other study(ies) available for celastrol methyl ester and Bone Loss, Perimenopausal

Article	Year
Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo. Drug design, development and therapy, 2020, Volume: 14 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Dose-Response Relationship, Drug; Female; Humans; Macrophages; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; Pentacyclic Triterpenes; Signal Transduction; X-Ray Microtomography	2020

Article

Year

Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo.

Drug design, development and therapy, 2020, Volume: 14

Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Dose-Response Relationship, Drug; Female; Humans; Macrophages; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; Pentacyclic Triterpenes; Signal Transduction; X-Ray Microtomography

2020